• Bevacizumab, sold under the brand name Avastin among others, is a monoclonal antibody medication used to treat a number of types of cancers and a specific...
    73 KB (6,440 words) - 02:59, 3 September 2024
  • most widely used VEGF pathway inhibitor on the market today is Bevacizumab. Bevacizumab binds to VEGF and inhibits it from binding to VEGF receptors. Angiogenesis...
    33 KB (3,229 words) - 19:54, 7 July 2024
  • day 1; Day 1: bevacizumab 5 mg/kg IV; repeat cycle every 2 weeks) are slightly dissimilar to FOLFIRINOX. Upfront FOLFOXIRI with bevacizumab can be followed...
    5 KB (574 words) - 21:05, 6 May 2024
  • antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that is approved to treat the "wet" type of...
    34 KB (2,721 words) - 07:40, 21 August 2024
  • Thumbnail for Atezolizumab
    September 2017. In May 2018, the use of atezolizumab in combination with bevacizumab (Avastin) and standard chemotherapy for some people with lung cancer...
    43 KB (4,164 words) - 02:04, 16 July 2024
  • prematurity. In a 2011 clinical trial comparing bevacizumab with conventional laser therapy, intravitreal bevacizumab monotherapy showed a significant benefit...
    30 KB (3,695 words) - 05:30, 17 June 2024
  • macular degeneration. They can involve monoclonal antibodies such as bevacizumab, antibody derivatives such as ranibizumab (Lucentis), or orally-available...
    14 KB (1,671 words) - 06:48, 24 August 2024
  • Thumbnail for Primary peritoneal carcinoma
    Benjamin E.; Sorosky, Joel I. (20 November 2007). "Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal...
    6 KB (503 words) - 19:09, 4 May 2024
  • at present." Biosimilars available in Australia include adalimumab, bevacizumab, enoxaparin, epoetin lambda, etanercept, filgrastim, follitropin alfa...
    95 KB (6,480 words) - 22:51, 13 May 2024
  • Thumbnail for Macular degeneration
    trial found that bevacizumab and ranibizumab had similar efficacy, and reported no significant increase in adverse events with bevacizumab. A 2014 Cochrane...
    90 KB (9,840 words) - 22:49, 25 August 2024
  • Thumbnail for Carmen Puliafito
    Champalimaud Foundation. Puliafito participated in research into the use of bevacizumab for the treatment of retinal disorders. The Los Angeles Times reported...
    12 KB (1,202 words) - 15:56, 10 July 2024
  • from cycle to cycle. FOLFIRI is often[citation needed] combined with bevacizumab, aflibercept, cetuximab or panitumumab to improve efficacy and response...
    4 KB (411 words) - 21:05, 6 May 2024
  • Thumbnail for Non-small-cell lung cancer
    disease who are not found to have either EGFR or ALK mutations may receive bevacizumab, which is a monoclonal antibody medication targeted against the vascular...
    51 KB (5,338 words) - 00:03, 27 August 2024
  • helped publicly launch the first antiangiogenic therapy for cancer, bevacizumab, starting with colorectal cancer. Co-founder Dr. William Li won the 2024...
    2 KB (143 words) - 00:40, 17 August 2024
  • Thumbnail for COVID-19
    include vasodilators, corticosteroids, immune therapies, lipoic acid, bevacizumab, and recombinant angiotensin-converting enzyme 2. In March 2020, the...
    288 KB (33,181 words) - 17:46, 2 September 2024
  • retina of the eye and other parts of the body. Drugs such as aflibercept, bevacizumab, ranibizumab, and pegaptanib can inhibit VEGF and control or slow those...
    40 KB (4,580 words) - 05:24, 3 June 2024
  • Thumbnail for Medical ultrasound
    "Advanced Hepatocellular Carcinoma: Early Evaluation of Response to Bevacizumab Therapy at Dynamic Contrast-enhanced US with Quantification—Preliminary...
    120 KB (13,902 words) - 14:14, 2 September 2024
  • Thumbnail for Hereditary hemorrhagic telangiectasia
    anti-VEGF antibody bevacizumab, for instance, has been used off-label in several studies. In a large clinical trial, bevacizumab infusion was associated...
    49 KB (5,782 words) - 05:29, 2 September 2024
  • to treatment with chemotherapy plus Bevacizumab, chemotherapy plus atezolizumab or chemotherapy plus Bevacizumab and atezolizumab. The chemotherapy used...
    59 KB (6,487 words) - 18:42, 27 December 2023
  • Thumbnail for Irinotecan
    the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab". Chinese Journal of Cancer. 35 (1): 102. doi:10...
    26 KB (2,315 words) - 04:55, 13 April 2024
  • Thumbnail for Nasal septum perforation
    It has been reported as a side effect of anti-angiogenesis drugs like bevacizumab. A perforated septum can vary in size and location, and is usually found...
    7 KB (860 words) - 18:28, 21 June 2024
  • (temsirolimus, sunitinib, sorafenib, pazopanib) and anti-angiogenic therapies (bevacizumab). "Clear cell carcinoma". NCI Dictionary of Cancer Terms. U.S. Department...
    3 KB (333 words) - 01:07, 3 December 2023
  • Thumbnail for Splenic infarction
    as vasoconstrictors used to treat esophageal varices, sumatriptan or bevacizumab. In a single-center retrospective cases review, people who were admitted...
    12 KB (1,229 words) - 22:44, 3 December 2023
  • Thumbnail for Macular telangiectasia
    modality. Recently, intravitreal injections of anti-VEGF agents, namely bevacizumab, a humanized monoclonal antibody targeted against pro-angiogenic, circulatory...
    19 KB (2,217 words) - 18:58, 27 September 2023
  • Thumbnail for Monoclonal antibody
    Fc region. MAbs approved by the FDA for cancer include: Alemtuzumab Bevacizumab Cetuximab Dostarlimab Gemtuzumab ozogamicin Ipilimumab Nivolumab Ofatumumab...
    49 KB (4,964 words) - 04:02, 9 August 2024
  • van Krieken JH, Dalesio O, Punt CJ (February 2009). "Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer". N Engl J Med. 360 (6):...
    23 KB (634 words) - 23:47, 16 August 2024
  • Thumbnail for Corneal neovascularization
    bevacizumab are currently used for treatment of various retinal disease. Anti-VEGF antibodies such as the application of ranibizumab or bevacizumab have...
    14 KB (1,530 words) - 14:10, 19 June 2024
  • Thumbnail for Erythropoietin
    Toceranib Tivozanib Vandetanib WHI-P 154 Antibodies: Alacizumab pegol Bevacizumab Icrucumab Ramucirumab Ranibizumab Decoy receptors: Aflibercept Others...
    31 KB (3,430 words) - 05:24, 28 August 2024
  • Thumbnail for Laryngeal papillomatosis
    monoclonal antibody against vascular endothelial growth factor (VEGF), bevacizumab, has shown promising result as an adjuvant therapy in the management...
    24 KB (2,555 words) - 17:10, 18 April 2024
  • that ultimately gained regulatory approval as intended effects, are: Bevacizumab (Avastin), used to slow the growth of blood vessels, has been used against...
    13 KB (1,267 words) - 14:53, 31 August 2024